Pipeline
FDA OKs Palatin's phase 3 DED trials on melanocortin agonist
Patient enrollment for MELODY-2 and MELODY-3 studies is expected to start Q4 2024.
Research
Blood type may determine retinal structures
Changes in macular and peripapillary RNFL thickness linked with certain blood types.
Pipeline
Ciliatech reports positive 36-month follow-up on glaucoma surgical implant
Results from SAFARI 1 and 2 studies demonstrate an IOP control of 8.0 mmHg and 70% reduction in medication dependence.
Research
Study identifies Vitamin D benefits for dry eye
Analyses find improved tear production and reduced lid hyperemia were among the advantages.
Pipeline
Ocuphire doses first patient in phase 3 presbyopia study on phentolamine solution
Already FDA approved as RYZUMVI for reversal of mydriasis, VEGA-3 topline data on POS 0.75% is expected by early 2025.
Research
New data supports NovaSight's binocular eye-tracking device for amblyopia control
Randomized controlled trial found that CureSight treatment achieved significantly greater visual acuity gains than eye patching.
Research
Do ocular allergies negate impact of pediatric ortho-k?
Potential link ties allergic conjunctivitis during ortho-k lens wear with increased axial length growth.
Business
Samsara Vision promotes industry veteran to COO
Former VP Jason Herod will oversee ongoing U.S.-based trials on the SING IMT intraocular telescope for late-stage AMD.
Products
Oculus adds dual testing to Easyfield VR perimetry device
New functionalities of Frequency Double Perimetry and Standard Automated Perimetry enable more accurate and precise detection of VF loss.
Research
Case Report: A rare occurrence of caruncle and conjunctival argyrosis
Homeopathic colloidal silver eye drops lead to a rare clinical diagnosis.
Business
Newly-launched Tern Therapeutics acquires ex-REGENXBIO gene therapies
Biotech company receives $15 million in funding to advance clinical development of TTX-381 and TTX-181 for treating ocular and CNS manifestations of CNL2 disease.
Pipeline
FDA grants IND clearance for BlueRock's primary photoreceptor disease cell therapy
New status paves the way for a phase 1/2a trial to evaluate the safety and efficacy of an induced pluripotent cell-derived candidate.
Research
Stress leads to IOP increase in glaucoma patients
New research evaluates the impact of psychological stress on patients with POAG.
Products
Bruder to rebrand and distribute Retaine MGD eye drop in the US
The preservative-free drop is expected to hit shelves in early 2025 as Eyeleve MGD.
Research
Does eye shape determine glaucoma severity?
Glaucoma may be more severe and progress faster in eyes with longer axial lengths.
Business
Advancing Eyecare purchases Eyefficient ophthalmic supplier
North American ophthalmic equipment companies join forces to serve ECPs, third-party distributors, and independent sales reps.
Research
SLT vs drops: Which is more effective for IOP reduction?
Meta-analysis evaluated efficacy of treatment options for primary open-angle glaucoma
Research
Suicide rates highest for female physicians, meta-analysis reports
Systematic review of generalized healthcare identifies females’ risk to be 76% higher than the general population.
Products
Alcon program guides clinical practices on advanced technology
Designed for surgeons and staff, the Accelerator program targets patient-focused outcomes for advanced technology IOL recommendations.
Research